Login / Signup

Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial.

Mathijs C BunckLennart TonneijckMarcel H A MuskietMark H H KramerIndra C Pieters-van den BosKaruna E W VendrikTrynke HoekstraMarco J BrunoMichaela DiamantDaniël H van RaalteDjuna L Cahen
Published in: Diabetes care (2016)
A 12-week treatment with liraglutide or sitagliptin only resulted in a brief and modest increase of plasma pancreatic enzyme concentrations in patients with type 2 diabetes. Apart from a minimal sitagliptin-induced increase in intraduodenal fluid secretion, pancreatic exocrine function was unaffected. The long-term clinical consequences of these discrete changes require further study.
Keyphrases
  • double blind
  • placebo controlled
  • open label
  • physical activity
  • clinical trial
  • weight loss
  • phase iii
  • diabetic rats
  • randomized controlled trial
  • phase ii
  • oxidative stress
  • endothelial cells